Irritable bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative colitis (UC) are serious chronic diseases affecting millions of patients worldwide. Studies of human chemokine biology has suggested C-C chemokine receptor 9 (CCR9) may be a key mediator of pro-inflammatory signaling. Discovery of agents that inhibit CCR9 may lead to new therapies for CD and UC patients. Herein we describe the evolution of a high content screening hit (1) into potent inhibitors of CCR9, such as azaindole 12.
Keywords: Crohn’s disease (CD); C–C chemokine receptor 9 (CCR9); Irritable bowel disease (IBD); Ulcerative colitis (UC).
Copyright © 2016 Elsevier Ltd. All rights reserved.